| abstract |
A ligand capable of labeling the aggregate tau protein in paired helical filaments (FHP) for use in an in vivo method to determine the stage of neurofibrillar degeneration associated with a tauopathy in a subject who is thought to have the disease, whose method comprises the stages of: (i) introducing the ligand into the subject, where the ligand is capable of crossing the blood brain barrier and is conjugated, chelated, or otherwise associated, with a detectable chemical group, (ii) determine the presence and / or the amount of ligand bound to the extracellular tau protein added in FHP in the medium temporal lobe of the subject's brain, (iii) correlate the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. |